| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.91 [0.84, 0.98] | | < 1 | | 0% | 6 studies (6/-) | 99.6 % | some concern | not evaluable | moderate | crucial | - |
| progression or deaths (PFS) | 0.96 [0.75, 1.23] | | < 1 | | 84% | 5 studies (5/-) | 63.0 % | some concern | not evaluable | moderate | important | - |
| CRR | 1.96 [1.21, 3.17] | | > 1 | | 0% | 1 study (1/-) | 99.7 % | NA | not evaluable | | non important | - |
| DOR | 0.40 [0.23, 0.67] | | < 1 | | 75% | 4 studies (4/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
| objective responses (ORR) | 0.65 [0.41, 1.04] | | > 1 | | 93% | 6 studies (6/-) | 3.7 % | some concern | serious | moderate | non important | - |
safety endpoints 00 |
| AE (any grade) | 0.52 [0.03, 8.39] | | < 1 | | 87% | 2 studies (2/-) | 67.6 % | some concern | not evaluable | moderate | non important | - |
| AE (grade 3-4) | 0.39 [0.17, 0.88] | | < 1 | | 95% | 4 studies (4/-) | 98.8 % | some concern | not evaluable | moderate | non important | - |
| AE (grade 3-5) | 0.76 [0.19, 3.00] | | < 1 | | 96% | 2 studies (2/-) | 65.4 % | some concern | not evaluable | moderate | non important | - |
| AE leading to death (grade 5) | 2.15 [1.27, 3.66] | | < 1 | | 60% | 4 studies (4/-) | 0.2 % | some concern | not evaluable | moderate | non important | - |
| AE leading to treatment discontinuation (any grade) | 0.80 [0.41, 1.56] | | < 1 | | 95% | 6 studies (6/-) | 74.7 % | some concern | not evaluable | moderate | non important | - |
| SAE (any grade) | 1.10 [0.81, 1.49] | | < 1 | | 76% | 4 studies (4/-) | 26.7 % | some concern | not evaluable | moderate | non important | - |
| STRAE (any grade) | 0.77 [0.47, 1.27] | | < 1 | | 91% | 6 studies (6/-) | 84.9 % | some concern | not evaluable | moderate | non important | - |
| TRAE (any grade) | 0.19 [0.08, 0.44] | | < 1 | | 93% | 5 studies (5/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
| TRAE (grade 3-4) | 0.22 [0.07, 0.66] | | < 1 | | 98% | 6 studies (6/-) | 99.7 % | some concern | serious | moderate | non important | - |
| TRAE leading to death (grade 5) | 1.37 [0.68, 2.76] | | < 1 | | 0% | 6 studies (6/-) | 19.3 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to discontinuation (any grade) | 0.78 [0.28, 2.17] | | < 1 | | 88% | 2 studies (2/-) | 68.3 % | some concern | not evaluable | moderate | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Abdominal pain TRAE (grade 3-4) | 2.15 [0.19, 24.47] | | < 1 | | 0% | 2 studies (2/-) | 27.1 % | some concern | not evaluable | moderate | non important | - |
| Acute kidney injury TRAE (grade 3-4) | 1.59 [0.24, 10.48] | | < 1 | | 0% | 2 studies (2/-) | 31.6 % | some concern | not evaluable | moderate | non important | - |
| Adrenal insufficiency TRAE (grade 3-4) | 2.41 [0.42, 13.66] | | < 1 | | 0% | 4 studies (4/-) | 16.1 % | some concern | not evaluable | moderate | non important | - |
| Alopecia TRAE (grade 3-4) | 1.36 [0.10, 17.71] | | < 1 | | 0% | 2 studies (2/-) | 40.9 % | some concern | not evaluable | moderate | non important | - |
| Anaemia TRAE (grade 3-4) | 0.12 [0.03, 0.45] | | < 1 | | 95% | 6 studies (6/-) | 99.9 % | some concern | serious | moderate | non important | - |
| Arthralgia TRAE (grade 3-4) | 2.85 [0.26, 30.86] | | < 1 | | 0% | 2 studies (2/-) | 19.6 % | some concern | not evaluable | moderate | non important | - |
| Arthritis TRAE (grade 3-4) | 1.36 [0.10, 17.75] | | < 1 | | 0% | 2 studies (2/-) | 40.8 % | some concern | not evaluable | moderate | non important | - |
| Asthenia TRAE (grade 3-4) | 0.70 [0.35, 1.40] | | < 1 | | 48% | 6 studies (6/-) | 84.2 % | some concern | serious | moderate | non important | - |
| Blood creatinine increased TRAE (grade 3-4) | 0.46 [0.04, 5.04] | | < 1 | | 0% | 2 studies (2/-) | 73.7 % | some concern | not evaluable | moderate | non important | - |
| Colitis TRAE (grade 3-4) | 3.23 [0.85, 12.29] | | < 1 | | 0% | 4 studies (4/-) | 4.3 % | some concern | not evaluable | moderate | non important | - |
| Constipation TRAE (grade 3-4) | 0.88 [0.22, 3.54] | | < 1 | | 0% | 4 studies (4/-) | 57.3 % | some concern | not evaluable | moderate | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.77 [0.35, 1.69] | | < 1 | | 0% | 6 studies (6/-) | 74.2 % | some concern | not evaluable | moderate | non important | - |
| Diabetes TRAE (grade 3-4) | 1.72 [0.30, 9.94] | | < 1 | | 0% | 4 studies (4/-) | 27.3 % | some concern | not evaluable | moderate | non important | - |
| Diarrhoea TRAE (grade 3-4) | 1.10 [0.58, 2.06] | | < 1 | | 0% | 4 studies (4/-) | 38.9 % | some concern | not evaluable | moderate | non important | - |
| Dyspnoea TRAE (grade 3-4) | 2.15 [0.19, 24.47] | | < 1 | | 0% | 2 studies (2/-) | 27.1 % | some concern | not evaluable | moderate | non important | - |
| Fatigue TRAE (grade 3-4) | 0.74 [0.39, 1.41] | | < 1 | | 31% | 6 studies (6/-) | 82.0 % | some concern | not evaluable | moderate | non important | - |
| Febrile neutropenia TRAE (grade 3-4) | 0.24 [0.04, 1.44] | | < 1 | | 0% | 2 studies (2/-) | 94.1 % | some concern | not evaluable | moderate | non important | - |
| Gastritis TRAE (grade 3-4) | 1.36 [0.10, 17.75] | | < 1 | | 0% | 2 studies (2/-) | 40.8 % | some concern | not evaluable | moderate | non important | - |
| Guillain-Barré syndrome TRAE (grade 3-4) | 1.36 [0.10, 17.71] | | < 1 | | 0% | 2 studies (2/-) | 40.9 % | some concern | not evaluable | moderate | non important | - |
| Hepatitis TRAE (grade 3-4) | 2.72 [0.53, 14.06] | | < 1 | | 0% | 4 studies (4/-) | 11.7 % | some concern | not evaluable | moderate | non important | - |
| Hypersensitivity TRAE (grade 3-4) | 0.46 [0.04, 5.04] | | < 1 | | 0% | 2 studies (2/-) | 73.7 % | some concern | not evaluable | moderate | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 1.21 [0.18, 8.00] | | < 1 | | 0% | 4 studies (4/-) | 42.0 % | some concern | not evaluable | moderate | non important | - |
| Hypophysitis TRAE (grade 3-4) | 3.36 [0.66, 17.24] | | < 1 | | 0% | 4 studies (4/-) | 7.4 % | some concern | not evaluable | moderate | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 2.60 [0.49, 13.77] | | < 1 | | 0% | 4 studies (4/-) | 13.2 % | some concern | not evaluable | moderate | non important | - |
| Increase AST TRAE (grade 3-4) | 1.36 [0.38, 4.94] | | < 1 | | 0% | 2 studies (2/-) | 31.9 % | some concern | not evaluable | moderate | non important | - |
| Increased ALT TRAE (grade 3-4) | 2.76 [0.55, 13.71] | | < 1 | | 0% | 2 studies (2/-) | 10.8 % | some concern | not evaluable | moderate | non important | - |
| Increased lipase level TRAE (grade 3-4) | 10.14 [2.36, 43.58] | | < 1 | | 0% | 2 studies (2/-) | 0.1 % | some concern | not evaluable | moderate | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 0.91 [0.06, 14.64] | | < 1 | | 0% | 2 studies (2/-) | 52.5 % | some concern | not evaluable | moderate | non important | - |
| Leucopenia TRAE (grade 3-4) | 0.07 [0.01, 0.76] | | < 1 | | 81% | 4 studies (4/-) | 98.5 % | some concern | not evaluable | moderate | non important | - |
| Myocarditis TRAE (grade 3-4) | 1.84 [0.31, 10.77] | | < 1 | | 0% | 4 studies (4/-) | 25.0 % | some concern | not evaluable | moderate | non important | - |
| Myositis TRAE (grade 3-4) | 1.21 [0.18, 7.95] | | < 1 | | 0% | 4 studies (4/-) | 42.3 % | some concern | not evaluable | moderate | non important | - |
| Nausea TRAE (grade 3-4) | 0.42 [0.16, 1.07] | | < 1 | | 38% | 6 studies (6/-) | 96.5 % | some concern | not evaluable | moderate | non important | - |
| Nephritis TRAE (grade 3-4) | 2.39 [0.45, 12.54] | | < 1 | | 0% | 4 studies (4/-) | 15.3 % | some concern | not evaluable | moderate | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.09 [0.02, 0.41] | | < 1 | | 90% | 6 studies (6/-) | 99.9 % | some concern | serious | moderate | non important | - |
| Pancreatitis TRAE (grade 3-4) | 3.13 [0.61, 15.95] | | < 1 | | 0% | 4 studies (4/-) | 8.6 % | some concern | not evaluable | moderate | non important | - |
| Pancytopenia TRAE (grade 3-4) | 0.11 [0.01, 0.91] | | < 1 | | 0% | 2 studies (2/-) | 97.9 % | some concern | not evaluable | moderate | non important | - |
| Pneumonitis TRAE (grade 3-4) | 3.34 [0.91, 12.23] | | < 1 | | 0% | 4 studies (4/-) | 3.5 % | some concern | not evaluable | moderate | non important | - |
| Pruritic rash TRAE (grade 3-4) | 1.36 [0.10, 17.75] | | < 1 | | 0% | 2 studies (2/-) | 40.8 % | some concern | not evaluable | moderate | non important | - |
| Pruritus TRAE (grade 3-4) | 2.37 [0.59, 9.50] | | < 1 | | 0% | 6 studies (6/-) | 11.2 % | some concern | serious | moderate | non important | - |
| Pyrexia TRAE (grade 3-4) | 0.62 [0.12, 3.24] | | < 1 | | 0% | 2 studies (2/-) | 71.6 % | some concern | not evaluable | moderate | non important | - |
| Rash TRAE (grade 3-4) | 2.99 [0.89, 10.03] | | < 1 | | 0% | 6 studies (6/-) | 3.9 % | some concern | not evaluable | moderate | non important | - |
| Sarcoidosis TRAE (grade 3-4) | 1.05 [0.07, 16.88] | | < 1 | | 0% | 2 studies (2/-) | 48.5 % | some concern | not evaluable | moderate | non important | - |
| Sepsis TRAE (grade 3-4) | 0.69 [0.08, 5.93] | | < 1 | | 0% | 2 studies (2/-) | 63.1 % | some concern | not evaluable | moderate | non important | - |
| Severe skin reaction TRAE (grade 3-4) | 2.46 [0.72, 8.32] | | < 1 | | 0% | 2 studies (2/-) | 7.5 % | some concern | not evaluable | moderate | non important | - |
| Stevens-Johnson syndrome TRAE (grade 3-4) | 1.36 [0.10, 17.71] | | < 1 | | 0% | 2 studies (2/-) | 40.9 % | some concern | not evaluable | moderate | non important | - |
| Stomatitis TRAE (grade 3-4) | 1.36 [0.10, 17.75] | | < 1 | | 0% | 2 studies (2/-) | 40.8 % | some concern | not evaluable | moderate | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 0.14 [0.04, 0.51] | | < 1 | | 85% | 6 studies (6/-) | 99.8 % | some concern | serious | moderate | non important | - |
| Thyroiditis TRAE (grade 3-4) | 1.47 [0.24, 9.02] | | < 1 | | 0% | 4 studies (4/-) | 34.0 % | some concern | not evaluable | moderate | non important | - |
| Vomiting TRAE (grade 3-4) | 0.40 [0.12, 1.27] | | < 1 | | 45% | 4 studies (4/-) | 94.0 % | some concern | not evaluable | moderate | non important | - |
AE (grade 3-4) endpoints 00 |
| Anaemia AE (grade 3-4) | 0.29 [0.02, 3.86] | | < 1 | | 99% | 2 studies (2/-) | 82.3 % | some concern | not evaluable | moderate | non important | - |
| Asthenia AE (grade 3-4) | 0.88 [0.32, 2.41] | | < 1 | | 78% | 2 studies (2/-) | 59.5 % | some concern | not evaluable | moderate | non important | - |
| Fatigue AE (grade 3-4) | 0.41 [0.14, 1.17] | | < 1 | | 75% | 2 studies (2/-) | 95.2 % | some concern | not evaluable | moderate | non important | - |
| Febrile neutropenia AE (grade 3-4) | 0.41 [0.01, 11.84] | | < 1 | | 81% | 2 studies (2/-) | 69.7 % | some concern | not evaluable | moderate | non important | - |
| Hypertension AE (grade 3-4) | 1.16 [0.29, 4.59] | | < 1 | | 77% | 2 studies (2/-) | 41.4 % | some concern | not evaluable | moderate | non important | - |
| Leucopenia AE (grade 3-4) | 0.14 [0.00, 5.94] | | < 1 | | 86% | 2 studies (2/-) | 84.5 % | some concern | not evaluable | moderate | non important | - |
| Nausea AE (grade 3-4) | 0.26 [0.04, 1.67] | | < 1 | | 67% | 2 studies (2/-) | 92.2 % | some concern | not evaluable | moderate | non important | - |
| Neutropenia AE (grade 3-4) | 0.08 [0.00, 29.10] | | < 1 | | 94% | 2 studies (2/-) | 79.0 % | some concern | not evaluable | moderate | non important | - |
| Thrombocytopenia AE (grade 3-4) | 0.14 [0.00, 12.34] | | < 1 | | 95% | 2 studies (2/-) | 79.8 % | some concern | not evaluable | moderate | non important | - |
| Vomiting AE (grade 3-4) | 0.36 [0.04, 2.88] | | < 1 | | 73% | 2 studies (2/-) | 83.2 % | some concern | not evaluable | moderate | non important | - |
